Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control of blood sugar levels than Sanofi’s Toujeo ...
The company said it has decided to stop distributing its once-daily basal insulin Tresiba (insulin degludec) in Germany - Europe's largest pharmaceutical market - in the wake of a "negative ...
Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback